Kyverna Therapeutics (KYTX) Earnings Analysis

Kyverna Therapeutics (KYTX) next reports earnings on 2026-08-11, consensus EPS -0.67 USD. Last quarter (2026-03-26) it beat with EPS -0.8 USD vs -0.845 USD est (+5.3%). It has beaten estimates in 3/4 recent quarters (75%). Trailing P/E -2.26.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does KYTX next report earnings?

Next earnings date2026-08-11
Consensus EPS estimate-0.67 USD
Revenue estimaten/a

KYTX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-26-0.8 USD-0.845 USD+5.3%Beat
2025-11-12-0.85 USD-0.97 USD+12.4%Beat
2024-11-13-0.8 USD-0.77 USD-3.9%Miss
2024-08-12-0.67 USD-0.7 USD+4.3%Beat

Beat rate: 3/4 (75%) over reported quarters with consensus data.

KYTX valuation and analyst view

Trailing P/E-2.26
Trailing EPS-2.58794 USD
Price / book2.29
Dividend yield0.00%
Market cap0.32B
Analyst consensusBuy (4 buy / 0 hold / 0 sell)
Avg price target25 USD

Related research pages

Frequently asked questions

When is Kyverna Therapeutics (KYTX)'s next earnings date?

Kyverna Therapeutics is next scheduled to report on 2026-08-11, with a consensus EPS estimate of -0.67 USD.

Did KYTX beat earnings last quarter?

In its 2026-03-26 report, KYTX posted EPS of -0.8 USD versus a -0.845 USD estimate — a beat of 5.3%.

What is KYTX's earnings track record?

Over the last 4 reported quarters with consensus data, KYTX beat estimates 3 times (75%).

What is KYTX's current P/E ratio and EPS?

KYTX trades at a trailing P/E of -2.26 on trailing EPS of -2.587938617537752 USD.

What do analysts rate KYTX?

Analyst consensus is "Buy" across 4 ratings (0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 25 USD.